Seoul Pregabalin Capsule 150 mg
Pregabalin 150mg
Hard capsule · Prescription medication
Seoul Pharmaceutical Co., Ltd.
MFDS item code 201902311 · Approved 2019.04.16
This product's status changed to Expired on 2024.04.16. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used in adults to alleviate peripheral and central neuropathic pain. It is also indicated as an adjunctive treatment for partial seizures in patients with epilepsy, whether accompanied by secondary generalized symptoms or not. Additionally, it is effective in improving symptoms of fibromyalgia. It provides assistance in the treatment of various neuro-related disorders.
This medication is administered orally as pregabalin, in 2 divided doses per day, regardless of food. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to “5. Patients with Renal Impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, thereafter the dose may be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, thereafter the dose may be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration schedule Initial dose (mg/day) Maximum dose (mg/day) ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, 100 mg, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as indicated in the administration schedule. b: The supplemental dose refers to a dose administered as an additional single dose. 6. Patients with Hepatic Impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behaviors, so patients and caregivers should inform healthcare professionals immediately if any symptoms of depression or mood changes occur. This drug should not be administered to patients with specific genetic lactose intolerance, and caution is warranted for patients with hypersensitivity. Diabetic patients may require adjustments in their blood sugar-lowering medication due to potential weight gain while taking this drug, which can affect blood sugar control. If symptoms of angioedema occur, the medication should be discontinued immediately, and elderly patients should be particularly cautious during the initial period of treatment due to the risk of accidents caused by dizziness or drowsiness. When discontinuing this medication, withdrawal symptoms such as insomnia, headache, and nausea may occur; therefore, consultation with healthcare professionals is necessary. Given the risk of drug abuse or dependence, a thorough review of the patient's mental health status and medication history is imperative. Patients with reduced kidney function may require dose adjustments, and careful administration is necessary for patients with heart disease. There is an increased risk of central nervous system depression when using this medication alongside opioid analgesics, so caution is advised. Pregnant women should avoid taking this medication in early pregnancy due to the risk of fetal malformations, and women of childbearing potential should use effective contraception. Lactating mothers are advised to avoid taking this medication as it may be transmitted through breast milk. The drug can cause dizziness and drowsiness, necessitating caution when driving or operating hazardous machinery. Severe skin reactions may rarely occur; if any unusual skin symptoms appear, the medication should be stopped immediately, and healthcare professionals should be consulted. In cases of overdose, symptoms such as confusion, drowsiness, and depression may arise, and appropriate treatment, such as dialysis, may be necessary if indicated. Keep out of reach of children and do not transfer to another container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is best to maintain a storage temperature between 15°C and 30°C.
A hard capsule with a white or pale yellow powder inside, with a white upper and lower part.
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin 150mg
Hard capsule · Prescription medication
Seoul Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.